Topotecan and cladribine with filgrastim support in relapsed, refractory and poor prognosis leukemias: A phase I-II study

被引：0
作者：
Silverman, LR [1 ]
Isola, L [1 ]
Brenner, R [1 ]
Gabrilove, J [1 ]
Mandeli, J [1 ]
机构：
[1] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6724
引用
收藏
页码：613S / 613S
页数：1
相关论文
共 50 条
  • [31] A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma
    Eslin, Don
    Zage, Peter E.
    Bergendahl, Genevieve
    Lewis, Elizabeth
    Roberts, William
    Kraveka, Jacqueline
    Mitchell, Deanna
    Isakoff, Michael S.
    Rawwas, Jawhar
    Wada, Randal K.
    Fluchel, Mark
    Brown, Valerie I.
    Ginn, Kevin
    Higgins, Timothy
    BeeravallyNagulapally, Abhinav
    Dykema, Karl
    Hanna, Gina
    Ferguson, William
    Saulnier Sholler, Giselle L.
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (05) : 1026 - 1034
  • [32] A Phase I/II Study of Pomalidomide and Dexamethasone with Growth Factor Support in Patients with Relapsed/Refractory Multiple Myeloma
    Manasanch, Elisabet E.
    Lee, Hans C.
    Patel, Krina K.
    Weber, Donna M.
    Lee, Hun Ju
    Thomas, Sheeba K.
    Chen, Wendy
    Oriabure, Onyeka
    Badillo, Maria
    Graham, Vivian
    Lei, Feng
    McCarthy, Magda S.
    Orlowski, Robert Z.
    Wang, Michael
    BLOOD, 2017, 130
  • [33] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma
    Pipas, JM
    Meyer, LP
    Rhodes, CH
    Cromwell, LD
    McDonnell, CE
    Kingman, LS
    Rigas, JR
    Fadul, CE
    JOURNAL OF NEURO-ONCOLOGY, 2005, 71 (03) : 301 - 305
  • [34] A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma
    J. Marc Pipas
    Louise P. Meyer
    C. Harker Rhodes
    Laurence D. Cromwell
    Carol E. McDonnell
    Linda S. Kingman
    James R. Rigas
    Camilo E. Fadul
    Journal of Neuro-Oncology, 2005, 71 : 301 - 305
  • [35] A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma.
    Reece, Donna E.
    Piza, Giovanni
    Trudel, Suzanne
    Pantoja, Manela
    Chen, Christine
    Mikhael, Joseph R.
    Kukreti, Vishal
    Stewart, Keith
    BLOOD, 2006, 108 (11) : 1009A - 1009A
  • [36] Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma
    Reece, Donna E.
    Masih-Khan, Esther
    Atenafu, Eshetu G.
    Jimenez-Zepeda, Victor H.
    Anglin, Peter
    Chen, Christine
    Kukreti, Vishal
    Mikhael, Joseph R.
    Trudel, Suzanne
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 168 (01) : 46 - 54
  • [37] Sequential topoisomerase I (topo I) and topoisomerase II (topo II) inhibitors in relapsed/refractory aggressive NHL: Results of CALGB 59906, a phase II study of doxorubicin and topotecan.
    Smith, SM
    Johnson, JL
    Niedzwiecki, D
    Eder, JP
    Canellos, GP
    Cheson, BD
    Bartlett, NL
    BLOOD, 2004, 104 (11) : 685A - 686A
  • [38] Phase II Study of 131I-MIBG with Five Days of Topotecan for Patients with Relapsed or Refractory Neuroblastoma (NB): Results of the French Study MITOP
    Defachelles, A. S.
    Bogart, E.
    Courbon, F.
    Oudoux, A.
    Cougnenc, O.
    Gambart, M.
    Corradini, N.
    Giraudet, A. L.
    Schleiermacher, G.
    Valteau-Couannet, D.
    Le Deley, M. C.
    Gauthier, H.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S321 - S321
  • [39] Safety and early efficacy assessment of liposomal daunorubicin (DaunoXome) in adults with refractory or relapsed acute myeloblastic leukaemia: a phase I-II study
    Fassas, A
    Buffels, R
    Anagnostopoulos, A
    Gacos, E
    Vadikolia, C
    Haloudis, P
    Kaloyannidis, P
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 308 - 315
  • [40] Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias (vol 21, pg 1050, 2003)
    Giles
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) : 1351 - 1351
12345